BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28181686)

  • 21. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
    Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
    Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
    Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
    Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelial to mesenchymal transition is associated with rapamycin resistance.
    Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
    Xu S; Zhang Z; Ogawa O; Yoshikawa T; Sakamoto H; Shibasaki N; Goto T; Wang L; Terada N
    Cell Biochem Biophys; 2014 Sep; 70(1):521-7. PubMed ID: 24744183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
    Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
    Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of BDNF/TrkB pathway promotes prostate cancer progression via induction of epithelial-mesenchymal transition and anoikis resistance.
    Li T; Yu Y; Song Y; Li X; Lan D; Zhang P; Xiao Y; Xing Y
    FASEB J; 2020 Jul; 34(7):9087-9101. PubMed ID: 32390303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
    Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
    Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bibenzyl from Dendrobium ellipsophyllum inhibits epithelial-to-mesenchymal transition and sensitizes lung cancer cells to anoikis.
    Chaotham C; Pongrakhananon V; Sritularak B; Chanvorachote P
    Anticancer Res; 2014 Apr; 34(4):1931-8. PubMed ID: 24692728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
    Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
    Wang X; Xu J; Wang H; Wu L; Yuan W; Du J; Cai S
    Biochem Biophys Res Commun; 2015 Jan; 456(1):320-6. PubMed ID: 25434997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IKK inhibitor suppresses epithelial-mesenchymal transition and induces cell death in prostate cancer.
    Ping H; Yang F; Wang M; Niu Y; Xing N
    Oncol Rep; 2016 Sep; 36(3):1658-64. PubMed ID: 27432067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
    Shah P; Gau Y; Sabnis G
    Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pien Tze Huang inhibits liver metastasis by targeting TGF-β signaling in an orthotopic model of colorectal cancer.
    Lin W; Zhuang Q; Zheng L; Cao Z; Shen A; Li Q; Fu C; Feng J; Peng J
    Oncol Rep; 2015 Apr; 33(4):1922-8. PubMed ID: 25653118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silencing Akt1 enhances the resistance of prostate cancer cells to starvation and inhibits starvation-induced lung metastasis through epithelial-mesenchymal transition in prostate cancer.
    Yang M; Liu H; Qiu GP; Gao F
    Med Oncol; 2021 Nov; 39(1):8. PubMed ID: 34761338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
    Lu KH; Chen PN; Hsieh YH; Lin CY; Cheng FY; Chiu PC; Chu SC; Hsieh YS
    Food Chem Toxicol; 2016 Nov; 97():177-186. PubMed ID: 27600294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.